Which has preferable earnings and valuation, TRAX or DFTX?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A Definium Therapeutics N/A N/A -$183.79M -$2.49 N/A

Is TRAX or DFTX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Definium Therapeutics N/A -100.30% -69.22%

Is HYPD or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% First Tracks Biotherapeutics N/A N/A N/A

Which has better earnings & valuation, TRAX or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is TRAX or PHXM more profitable?

Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A PHAXIAM Therapeutics N/A N/A N/A

Do analysts rate LIAN or TRAX?

First Tracks Biotherapeutics has a consensus target price of $41.00, indicating a potential upside of 15.43%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 First Tracks Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89

Which has better earnings & valuation, LIAN or TRAX?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A

Is LIAN or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% First Tracks Biotherapeutics N/A N/A N/A

Which has preferable earnings and valuation, TRAX or ADIL?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A

Is TRAX or ADIL more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Adial Pharmaceuticals N/A -162.82% -127.58%

First Tracks Biotherapeutics (TRAX) Competitors

$35.52 -2.12 (-5.63%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$35.36 -0.16 (-0.44%)

As of 07/24/2026 07:34 PM Eastern

Compare

TRAX vs. DFTX, HYPD, PHXM, LIAN, and ADIL

Should you buy First Tracks Biotherapeutics stock or one of its competitors? MarketBeat compares First Tracks Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with First Tracks Biotherapeutics include Definium Therapeutics (DFTX), Hyperion DeFi (HYPD), PHAXIAM Therapeutics (PHXM), LianBio (LIAN), and Adial Pharmaceuticals (ADIL). These companies are all part of the "biotechnology" industry.

How does First Tracks Biotherapeutics compare to Definium Therapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Definium Therapeutics (NASDAQ:DFTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

First Tracks Biotherapeutics' return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Definium Therapeutics	N/A	-100.30%	-69.22%

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

In the previous week, Definium Therapeutics had 6 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 7 mentions for Definium Therapeutics and 1 mentions for First Tracks Biotherapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.94 beat Definium Therapeutics' score of 0.49 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
First Tracks Biotherapeutics	Positive
Definium Therapeutics	Neutral

First Tracks Biotherapeutics currently has a consensus target price of $41.00, suggesting a potential upside of 15.43%. Definium Therapeutics has a consensus target price of $51.15, suggesting a potential upside of 18.49%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Definium Therapeutics beats First Tracks Biotherapeutics on 8 of the 12 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Hyperion DeFi currently has a consensus price target of $6.95, indicating a potential upside of 176.89%. First Tracks Biotherapeutics has a consensus price target of $41.00, indicating a potential upside of 15.43%. Given Hyperion DeFi's higher probable upside, analysts clearly believe Hyperion DeFi is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, Hyperion DeFi and Hyperion DeFi both had 1 articles in the media. Hyperion DeFi's average media sentiment score of 1.87 beat First Tracks Biotherapeutics' score of 0.94 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperion DeFi	Very Positive
First Tracks Biotherapeutics	Positive

First Tracks Biotherapeutics has lower revenue, but higher earnings than Hyperion DeFi. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	46.98	-$45.31M	-$9.95	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

First Tracks Biotherapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
First Tracks Biotherapeutics	N/A	N/A	N/A

25.8% of Hyperion DeFi shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Hyperion DeFi beats First Tracks Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to PHAXIAM Therapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
PHAXIAM Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

First Tracks Biotherapeutics currently has a consensus price target of $41.00, suggesting a potential upside of 15.43%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe First Tracks Biotherapeutics is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for First Tracks Biotherapeutics and 0 mentions for PHAXIAM Therapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.94 beat PHAXIAM Therapeutics' score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
First Tracks Biotherapeutics	Positive
PHAXIAM Therapeutics	Neutral

Summary

First Tracks Biotherapeutics beats PHAXIAM Therapeutics on 5 of the 7 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to LianBio?

LianBio (NASDAQ:LIAN) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

First Tracks Biotherapeutics has a consensus target price of $41.00, indicating a potential upside of 15.43%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

First Tracks Biotherapeutics' return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
First Tracks Biotherapeutics	N/A	N/A	N/A

74.8% of LianBio shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for First Tracks Biotherapeutics and 0 mentions for LianBio. First Tracks Biotherapeutics' average media sentiment score of 0.94 beat LianBio's score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
First Tracks Biotherapeutics	Positive

Summary

First Tracks Biotherapeutics beats LianBio on 7 of the 11 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Adial Pharmaceuticals?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

First Tracks Biotherapeutics currently has a consensus price target of $41.00, suggesting a potential upside of 15.43%. Adial Pharmaceuticals has a consensus price target of $17.17, suggesting a potential upside of 517.51%. Given Adial Pharmaceuticals' higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

16.4% of Adial Pharmaceuticals shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

First Tracks Biotherapeutics' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

In the previous week, First Tracks Biotherapeutics and First Tracks Biotherapeutics both had 1 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.89 beat First Tracks Biotherapeutics' score of 0.94 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
First Tracks Biotherapeutics	Positive
Adial Pharmaceuticals	Very Positive

Summary

First Tracks Biotherapeutics and Adial Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get First Tracks Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAX vs. The Competition

Export

Metric	First Tracks Biotherapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.31B	$443.68M	$7.06B	$12.20B
Dividend Yield	N/A	3.90%	2.67%	9.41%
P/E Ratio	-19.30	3.49	27.14	23.63
Price / Sales	N/A	6,592.41	582.30	111.98
Price / Cash	N/A	13.13	49.81	58.78
Price / Book	N/A	83.70	10.28	6.01
Net Income	N/A	-$96.07M	$3.60B	$331.99M
7 Day Performance	-2.71%	-0.66%	-1.27%	-0.63%
1 Month Performance	121.58%	-1.54%	-1.67%	-3.04%
1 Year Performance	N/A	55.33%	18.25%	13.30%

First Tracks Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAX First Tracks Biotherapeutics	2.1816 of 5 stars	$35.52 -5.6%	$41.00 +15.4%	N/A	$1.31B	N/A	N/A	N/A	Analyst Forecast
DFTX Definium Therapeutics	3.2355 of 5 stars	$43.65 +2.0%	$49.23 +12.8%	+342.3%	$4.35B	N/A	N/A	40	Analyst Forecast Gap Up
HYPD Hyperion DeFi	3.5487 of 5 stars	$2.85 +4.8%	$6.95 +143.9%	-67.4%	$43.21M	$810K	N/A	40	Positive News
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
LIAN LianBio	N/A	$0.08 +32.5%	N/A	+7.9%	$8.65M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAX) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. DFTX, HYPD, PHXM, LIAN, and ADIL

How does First Tracks Biotherapeutics compare to Definium Therapeutics?

Summary

How does First Tracks Biotherapeutics compare to Hyperion DeFi?

Summary

How does First Tracks Biotherapeutics compare to PHAXIAM Therapeutics?

Summary

How does First Tracks Biotherapeutics compare to LianBio?

Summary

How does First Tracks Biotherapeutics compare to Adial Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. DFTX, HYPD, PHXM, LIAN, and ADIL

How does First Tracks Biotherapeutics compare to Definium Therapeutics?

Do insiders and institutionals have more ownership in TRAX or DFTX?

Is TRAX or DFTX more profitable?

Which has preferable earnings and valuation, TRAX or DFTX?

Does the media refer more to TRAX or DFTX?

Do analysts rate TRAX or DFTX?

Summary

How does First Tracks Biotherapeutics compare to Hyperion DeFi?

Do analysts prefer HYPD or TRAX?

Does the media prefer HYPD or TRAX?

Which has better earnings & valuation, HYPD or TRAX?

Is HYPD or TRAX more profitable?

Do institutionals and insiders believe in HYPD or TRAX?

Summary

How does First Tracks Biotherapeutics compare to PHAXIAM Therapeutics?

Do insiders and institutionals hold more shares of TRAX or PHXM?

Is TRAX or PHXM more profitable?

Which has better earnings & valuation, TRAX or PHXM?

Do analysts prefer TRAX or PHXM?

Does the media refer more to TRAX or PHXM?

Summary

How does First Tracks Biotherapeutics compare to LianBio?

Which has better earnings & valuation, LIAN or TRAX?

Do analysts rate LIAN or TRAX?

Is LIAN or TRAX more profitable?

Do institutionals and insiders hold more shares of LIAN or TRAX?

Does the media favor LIAN or TRAX?

Summary

How does First Tracks Biotherapeutics compare to Adial Pharmaceuticals?

Which has preferable earnings and valuation, TRAX or ADIL?

Do analysts prefer TRAX or ADIL?

Do insiders & institutionals have more ownership in TRAX or ADIL?

Is TRAX or ADIL more profitable?

Does the media prefer TRAX or ADIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools